SLC5A2 and chronic kidney disease: The aim of this study is to perform a systematic review and meta-analysis of RCTs assessing the effect of SGLT-2 inhibitors on cardiovascular and renal outcomes according to baseline CKD status in individuals with or without type 2 diabetes.